A drug screening platform for protein expression levels in neurological disorders
BioTechniques · 2025
DOI: 10.1080/07366205.2025.2484094 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioTechniques, 2025. Verfasst von Farida Emran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Research in Neuroscience, Research Institute, McGill University Health Centre, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Nervous System Diseases, High-Throughput Screening Assays, Proteins. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Institutes of Health Research, GeneSpark and the International Kleefstra Syndrome Foundation, Sandra and Alain Bouchard Foundation.
Abstract (Originalsprache)
Neurological and psychiatric diseases and disorders affect more than half of the population. Many of these diseases are caused by the malfunctioning of protein synthesis, where too little or too much production of a protein harms a cell and its functions within the brain. We developed a drug screening platform to identify compounds that target the primary cause of these diseases, namely protein expression amounts. This cellular assay monitors protein expression of a target disease gene along with the protein expression of a control gene using the Protein Quantitation Ratioing (PQR) technique. PQR tracks protein concentration using fluorescence. We used human cells and CRISPR-Cas9 genome editing to insert the Protein Quantitation Reporter into target genes. These cells are used in high-throughput drug screening measuring the fluorescence as the assay. Drug hits can be validated using the same PQR technique or animal models of the disease. Inserting a Protein Quantitation Reporter (PQR) into a gene allows for measuring endogenous protein amounts in single living cells over time. Using protein quantitation as a readout, a drug screening assay targeting diseases caused by abnormal protein levels can identify compounds capable of restoring these proteins to their normal concentrations. Human cell lines that express high levels of a target disease gene can be chosen for PQR knock-in to facilitate the evaluation of CRISPR-Cas9 guide RNAs and the DNA repair template containing the PQR. Genome-editing induced pluripotent stem cells to knock in a PQR provides an unlimited supply of differentiated cells, such as neurons. High-throughput drug screening can be performed using PQR knock-in cells to quantify the target protein in cells before, during, and after drug administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Research in Neuroscience, Research Institute, McGill University Health Centre, Montréal, Québec, Canada.
- Departments of Medicine and Neurology & Neurosurgery, McGill University, Montréal, Québec, Canada.
ORCID-Profile: Brian E Chen
Förderung
- Canadian Institutes of Health Research
- GeneSpark and the International Kleefstra Syndrome Foundation
- Sandra and Alain Bouchard Foundation
- Weston Brain Institute
- Québec Consortium for Drug Discovery
- Consortium Québécois sur la Découverte du Médicament
Zitieren
APA
Emran, F., Kays, I., Lo, C. A., Li, Y., & Chen, B. E. (2025). A drug screening platform for protein expression levels in neurological disorders. BioTechniques. https://doi.org/10.1080/07366205.2025.2484094
Vancouver
Emran F, Kays I, Lo CA, Li Y, Chen BE. A drug screening platform for protein expression levels in neurological disorders. BioTechniques. 2025. doi:10.1080/07366205.2025.2484094
BibTeX
@article{Emran2025,
author = {Emran, Farida and Kays, Ibrahim and Lo, Chiu-An and Li, Yueyang and Chen, Brian E},
title = {A drug screening platform for protein expression levels in neurological disorders},
journal = {BioTechniques},
year = {2025},
doi = {10.1080/07366205.2025.2484094}
}
EUVIMED